Skip to content

Effect of rTMS combined with sertraline on Inflammatory levels and Its correlation in adolescent patients with depression

Effect of rTMS combined with sertraline on Inflammatory levels and Its correlation in adolescent patients with depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112243
Enrollment
Unknown
Registered
2025-11-11
Start date
2025-02-20
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent depression

Interventions

rTMS group:The treatment combining rTMS and sertraline
Sham stimulation group:Sham stimulation combined with sertraline treatment

Sponsors

The Affiliated Xuzhou Oriental Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1.The patient meets the diagnostic criteria for depression in the International Classification of Diseases, 10th Revision (ICD-11), with an episode duration of at least 2 weeks. 2.Age 12–18 years, Han ethnicity. 3.The 24-item Hamilton Depression Rating Scale (HAMD-24) score is >=20. 4.The patient's personal information, medical history, medication use, and data from various assessment scales are complete and suitable for in-depth analysis. 5.Informed consent has been signed.

Exclusion criteria

Exclusion criteria: 1. Patients with bipolar affective disorder or other mood disorders. 2. Patients with severe somatic or neurological diseases. 3. Patients with contraindications or allergies to the medications used in this study, non-right-handed individuals, those with a history of epilepsy, or those with abnormal electroencephalogram (EEG) findings. 4. Patients with incomplete clinical data or who are unable to cooperate with the treatment. 5. Patients with scalp wounds or trauma, or those with metal implants in the body. 6. Patients with other cognitive impairments that prevent cooperation with treatment or follow-up.

Design outcomes

Primary

MeasureTime frame
suPAR;CRP;IL-6;

Countries

China

Contacts

Public ContactCaiyi Zhang

The Affiliated Xuzhou Oriental Hospital of Xuzhou Medical University

100002018003@xzhmu.edu.cn+86 137 7588 9105

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026